Michela Meregaglia1, Helen Banks2, Giovanni Fattore3. 1. CeRGAS, Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy michela.meregaglia@unibocconi.it. 2. CeRGAS, Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy. 3. CeRGAS, Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy.
Abstract
BACKGROUNDS AND AIMS: Despite recent advances in medical therapies for inflammatory bowel disease [IBD], little is known about their impact on inpatient management. Our objectives were to explore hospitalisation and surgery trends for all IBD patients in Italy at three time points over 7 years. METHODS: National hospital discharge records were retrospectively reviewed for all admissions with a Crohn's disease [CD, 555*] or ulcerative colitis [UC, 556*] diagnosis in 2005, 2008, and 2011. Quantitative variables [mean, standard deviation] and categorical variables [frequencies] were described; comparison among admission-years was made by analysis of variance and chi-square tests. A multivariate logistic regression analysis was performed to identify predictors of surgery risk regarding demographics, inpatient management, and clinical features; p-values ≤ 0.05 were considered statistically significant. RESULTS: Overall, 109657 hospitalisations occurred over the 3 years, with a decreasing trend observed in UC admissions. Mean age was higher in UC [50.1±19.7] than in CD [43.2±21.9]. The number of paediatric admissions rose from 3637 to 4372 between 2005 and 2011. An increasing proportion of CD [from 12.4% to 14.6%] and UC [from 5.8% to 8.0%] admissions reported a digestive system-related, surgical diagnosis-related group in the same period; overall, gastrointestinal surgical admissions increased from 3299 to 3964. In regression analysis, male gender, age, admission year, northern university hospital, disease localisation, and cancer as independent factors significantly affected the likelihood of surgery. CONCLUSIONS: Despite a reduction in total IBD hospitalisations, surgical and paediatric admissions rose over time. Further study is needed to clarify benefits associated with new drugs in terms of inpatient management.
BACKGROUNDS AND AIMS: Despite recent advances in medical therapies for inflammatory bowel disease [IBD], little is known about their impact on inpatient management. Our objectives were to explore hospitalisation and surgery trends for all IBD patients in Italy at three time points over 7 years. METHODS: National hospital discharge records were retrospectively reviewed for all admissions with a Crohn's disease [CD, 555*] or ulcerative colitis [UC, 556*] diagnosis in 2005, 2008, and 2011. Quantitative variables [mean, standard deviation] and categorical variables [frequencies] were described; comparison among admission-years was made by analysis of variance and chi-square tests. A multivariate logistic regression analysis was performed to identify predictors of surgery risk regarding demographics, inpatient management, and clinical features; p-values ≤ 0.05 were considered statistically significant. RESULTS: Overall, 109657 hospitalisations occurred over the 3 years, with a decreasing trend observed in UC admissions. Mean age was higher in UC [50.1±19.7] than in CD [43.2±21.9]. The number of paediatric admissions rose from 3637 to 4372 between 2005 and 2011. An increasing proportion of CD [from 12.4% to 14.6%] and UC [from 5.8% to 8.0%] admissions reported a digestive system-related, surgical diagnosis-related group in the same period; overall, gastrointestinal surgical admissions increased from 3299 to 3964. In regression analysis, male gender, age, admission year, northern university hospital, disease localisation, and cancer as independent factors significantly affected the likelihood of surgery. CONCLUSIONS: Despite a reduction in total IBD hospitalisations, surgical and paediatric admissions rose over time. Further study is needed to clarify benefits associated with new drugs in terms of inpatient management.
Authors: Andrea Szentesi; Emese Tóth; Emese Bálint; Júlia Fanczal; Tamara Madácsy; Dorottya Laczkó; Imre Ignáth; Anita Balázs; Petra Pallagi; József Maléth; Zoltán Rakonczay; Balázs Kui; Dóra Illés; Katalin Márta; Ágnes Blaskó; Alexandra Demcsák; Andrea Párniczky; Gabriella Pár; Szilárd Gódi; Dóra Mosztbacher; Ákos Szücs; Adrienn Halász; Ferenc Izbéki; Nelli Farkas; Péter Hegyi Journal: PLoS One Date: 2016-10-24 Impact factor: 3.240
Authors: Mehul V Raval; Erin Wymore; Martha-Conley E Ingram; Yao Tian; Julie K Johnson; Jane L Holl Journal: Trials Date: 2020-11-16 Impact factor: 2.279
Authors: Aman K Dheri; M Ellen Kuenzig; David R Mack; Sanjay K Murthy; Gilaad G Kaplan; Jessy Donelle; Glenys Smith; Eric I Benchimol Journal: J Crohns Colitis Date: 2021-12-18 Impact factor: 9.071